Cut FDA Submission Timelines by 60% with Freya Fusion, Freyr’s AI-powered, automation-first submission platform.

With built-in intelligence for FDA eCTD publishing and validation, Freya Fusion helps you eliminate manual errors, streamline workflows, and achieve faster approvals — so your teams can focus on strategy, not spreadsheets. Launch smarter. Launch faster. Launch with Freya Fusion!

Let Freya Fusion Shorten Your FDA Path

Get Faster FDA Approvals

Reduced

Submission Timelines: 
90 days → 30 days

 

40%

Reduction in 
QC Efforts

 

99.8%

Accuracy 
Improvement

 

Adopted by

Top US Pharma 
Innovators

Why Choose Freya Fusion?

eCTD Automation

End-to-end automation for eCTD-ready submissions — from dossier assembly to FDA validation — in a single click.

QC Automation

Eliminate manual review fatigue with built-in AI QC that validates hyperlinks, bookmarks, metadata, and XML structures instantly.

FDA ESG-Ready Output

Generate validated, ESG-ready submissions with automatic tracking and versioning — no rework, no delays, no manual errors.

Cloud-Based, Secure & Compliant

Enterprise-grade security, audit trails, and role-based access ensure compliance at every stage.

Talk to our FDA Submission Experts Today!

Frequently Asked Questions

 

Freya Fusion is Freyr’s AI-driven FDA submission automation platform that simplifies and accelerates eCTD publishing, validation, and submission processes. It automates manual tasks, ensures error-free regulatory submissions, and enables faster drug approvals through built-in intelligence and cloud-based efficiency.

By leveraging automation and AI validation, Freya Fusion can help reduce submission timelines by up to 60% — transforming a 90-day NDA or BLA submission process into just 30 days. The platform eliminates repetitive manual QC, integrates with DMS systems, and streamlines every stage of eCTD preparation.

Freya Fusion offers end-to-end automation, AI-based QC for bookmarks, hyperlinks, and metadata, and ESG-ready FDA outputs with zero manual rework. With 99.8% accuracy and a proven track record across top global pharma clients, it’s the industry benchmark for regulatory submission excellence.

Yes. Freya Fusion supports complete eCTD lifecycle management, covering IND, NDA, ANDA, BLA, and post-approval submissions like Annual Reports, Renewals, and Variations. It complies with multiple regulatory standards including FDA v4.0, EMA, Health Canada, TGA, PMDA, and EAEU formats.

Absolutely. Freya Fusion is built for FDA 21 CFR Part 11 compliance, offering robust audit trails, access controls, and electronic signatures. It’s hosted on ISO 27001-certified cloud infrastructure, ensuring the highest standards of data security and regulatory compliance.

Freya Fusion seamlessly integrates with Document Management Systems (DMS) and Regulatory Information Management (RIM) platforms. Its open architecture allows data synchronization, real-time submission tracking, and unified dashboards — all while maintaining regulatory traceability.

Freya Fusion is trusted by top 20 global pharmaceutical and biotech innovators. With over 200,000 successful eCTD and regulatory submissions delivered, the platform has proven to reduce costs, improve speed, and enhance compliance across regions including the US, EU, Japan, and Health Canada.

Freya Fusion features built-in AI-based Quality Control (QC) that validates hyperlinks, bookmarks, XML outputs, and metadata in real time. This ensures 99.8% right-first-time accuracy and near-zero manual rework — drastically improving both submission quality and reviewer confidence.

Celebrating Customers Success

 

Medicinal Products

Publishing and Submission

UK

We would like to appreciate Freyr’s quick TAT to push through an urgent submission required by the FDA. Their efficiency, diligence, excellence, sense of urgency, and priority are deeply flexibility.

Please keep up the great work as we have many milestones to achieve over the next year.

Ed Venkat

Global CMC Technical Lead

 

Medicinal Products

Publishing and Submission

UK

I am sure you have heard by now that we have received our first-ever approval from the FDA for our Brands division. This is a major milestone for us as well as for my team here in Reg Ops. I would be remiss if I didn’t point out that we would not have been able to do this without the help of your dedicated team. From the original filing, then the following year of responses, all helped get us to final approval.

Thank you Freyr team for a job well done!

Michael Bellero

Sr. Director, Head of Regulatory Operations

 

Medical Devices

Publishing and Submission​

USA

Communication and on the ground knowledge or RA requirements - this has been our experience for India. Quick to response and willing to have calls to explain requirements. Very happy with the RA work conducted in India, would use for other markets. We are satisfied. ​

Director of Regulatory Affairs​

France-based, Leading Global Supplier of Women Healthcare Products Company​